Meridian Bioscience predicts strong revenue from diagnostic sales; Switch from Windows to Linux to reduce med device hackability;

 @FierceMedDev: Moving on from the Duet recall, Covidien gets a 510(k) for its next-gen surgical stapler. News | Follow @FierceMedDev

 @MarkHFierce: Stent use can help certain patients more than medical therapy if used on the early side. Release | Follow @MarkHFierce

 @DamianFierce: Joining other big shots in the device game, Medtronic has opened an R&D center in China. Report | Follow @DamianFierce

> Meridian Bioscience ($VIVO) is predicting a strong fiscal 2013, planning to notch between $190 million to $195 million on the strength of new diagnostic kits. Article

> Amid all the concern over the hackability of networked medical devices, one tech blogger suggests switching from Windows to Linux could boost software security. Story

> A new heart separation device improved three-year outcomes in heart failure patients. Release

> In Kenya, AIDS-prevention groups are lobbying the government to approve two minimally-invasive circumcision devices, citing study results saying circumcised men reduced risk of HIV infection by 65%. News

> The worldwide market for cancer diagnostics will explode over the next decade, according to a new study from ReportsnReports. More

>  A new device that mechanically removed stroke-causing clots from blocked brain arteries performed well in a recent clinical trial. Item

Biotech News

 @FierceBiotech: Special report: The Alzheimer's pipeline... What's next? Report | Follow @FierceBiotech

 @JohnCFierce: Resverlogix touts positive PhIIb atherosclerosis data, sets sights on PhIII deal. More | Follow @JohnCFierce

 @RyanMFierce: What changes will Roche vet Pascal Soriot make as CEO of AstraZeneca? More | Follow @RyanMFierce

> Alnylam reaps $29M harvest in new ag bio deal with Monsanto. News

> Analysis: Where will Pascal Soriot take AstraZeneca now? More

> FDA OK for HIV pill Quad sets up potential confrontation over Gilead's price. Article

Pharma News

 @FiercePharma: AstraZeneca's gain is Roche's loss: Stock down 1% after $AZN woos away Pascal Soriot for CEO job. More | Follow @FiercePharma

> Forest adopts 'poison pill' to fend off Icahn. Report

> AstraZeneca entices Roche exec to take on CEO challenge. News

> Gilead draws early fire for new HIV med's $28K price. Story

Biotech Research News

> Acorda's drug treats nerve damage-related ED in preclinical test. Article

> Novira raises $23M for hepatitis B/HIV drug work. News

> Genentech, U. Minnesota scientists discover new colon cancer red flags. Story

> Johns Hopkins team turning blood cells into stem cells. More

> Melanoma stem cells may carry provocative drug target. Item

Pharma Manufacturing News

> Drugmaker EirGen thinks plan to put waste station nearby stinks. More

> Sun says FDA clears plants where Marshalls seized products in 2009. News

> CSL, whose vaccine was tied to convulsions, gets FDA closeout letter. Story

> Hospira commits to 200 jobs, $85M investment, at troubled plant. Report

Suggested Articles

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.

Insulet announced new agreements with Abbott and Dexcom to connect their continuous glucose monitors with its upcoming tubeless, digital insulin pump,

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.